NCATS to Receive FNIH Sanders Partnership Award
The Foundation for the National Institutes of Health (FNIH) will award the 2025 Charles A. Sanders, MD, Partnership Award to three groups or organizations. Within NIH, the recipient is the National Center for Advancing Translational Sciences (NCATS). The Partnership Award recognizes people or organizations that have made significant contributions to the FNIH’s work in support of NIH’s mission.
NCATS is the NIH lead for the Accelerating Medicines Partnership® (AMP) Bespoke Gene Therapy Consortium, which aims to streamline manufacturing and preclinical testing for gene therapies for rare diseases. It played a critical role in the 2020 launch and execution of the Accelerating COVID-19 Therapeutic Interventions and Vaccines program, which helped identify treatments.
NCATS participates in several AMP programs as well as the Biomarkers Consortium and design phase projects focusing on development of regulatory approval for pediatric medical devices, new approach methodologies (NAMs) and drugs for ultra-rare cancers.
The award is named for the founding chairman of FNIH’s board of directors. The recipients will be awarded at a ceremony in October in Washington.
FNIH President and CEO Dr. Julie Gerberding said, “We are deeply grateful for their generous commitment to team science and investment in the future of biomedical research.”